Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The biopharma industry showed signs of recovery in the third quarter (Q3) of 2024, with increased investor optimism following the interest rate cuts by the US Federal Reserve in September 2024, according to GlobalData. 29 October 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
USA-based rare seizure specialist Marinus Pharmaceuticals saw its shares crash, falling nearly 83% to $1.36, after it revealed that a trial failed to meet early stopping criteria. 16 April 2024
Biotechnology
The Phase I trial of NMRA-266 has been placed on clinical hold by the US Food and Drug Administration (FDA), said the drug’s developer, Massachusetts, USA-based based brain disease biotech Neumora Therapeutics. 15 April 2024
Pharmaceutical
A US judge has dismissed a legal claim from pharma major Eli Lilly alleging that an online pharmacy illegally sold an unauthorized compounded version of the company's dual GIP and GLP-1 receptor agonist tirzepatide. 15 April 2024
Biotechnology
Among last week’s regulatory news, the US Food and Drug Administration (FDA) approved an additional indication for pharma major Bristol Myers Squibb and 2seventy bio’s Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. The US Justice Department filed a False Claims Act complaint against Regeneron regarding the pricing of its eye diseases drug Eylea. On the M&A front, Vertex Pharma last Wednesday announced that it is acquiring fellow USA-based Alpine Immune Sciences and its kidney disease candidate povetacicept for $4.6 billion. Also of note, Arvinas last week entered into a potential $1 billion plus licensing deal with Swiss pharma giant Novartis for its prostate cancer candidate ARV-766. 14 April 2024
Pharmaceutical
Available evidence does not support a link between GLP-1 receptor agonists with suicidal and self-injurious thoughts and actions. 12 April 2024
Pharmaceutical
USA-based Nectero Medical has raised $96 million in a Series D financing round led by Norwest Venture Partners, with significant investments also from Boston Scientific, BioStar Capital and others. 12 April 2024
Biotechnology
US mRNA medicines company Moderna has paused its efforts to build a manufacturing facility in Kenya while it determines future demand for mRNA vaccines on the African continent. 12 April 2024
Biotechnology
The US Department of Justice (DoJ) says it has filed a complaint under the False Claims Act (FCA) against Regeneron. 11 April 2024
Biotechnology
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics for the design of a Phase IIIb trial of NurOwn (MSC-NTF cells). 10 April 2024
Biotechnology
Swiss ophthalmology firm Oculis Holding today announced the appointment of Dr Snehal Shah, executive leader with over two decades of research and development (R&D) and regulatory experience, to the role of president of R&D. 10 April 2024
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
8 November 2024
24 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze